Pablo Graiver is CEO of Antidote.
Ozgun Demir is the director, digital strategy at Novartis.
Wout Brusselaers is CEO of Deep 6 AI.
Sundeep Bhan is cofounder and CEO of Prognos.
Ryan Billings is the senior director, digital innovation at Amag Pharmaceuticals.
Heather Bell is SVP, global head of digital and analytics of Sanofi.
Jay Appel is executive director of Bristol-Myers Squibb.
The Food and Drug Administration regulates more than a third of the U.S. economy. And its new commissioner, Scott Gottlieb, is trying to shake up how it does so.
Pharma companies are likely to put up aggressive resistance to the measure, introduced earlier this month.
When Ortho Clinical Diagnostics lived under the roof of Johnson & Johnson, it had the luxury of focusing on its product and service mix — and not a whole lot else.
The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.
PhRMA wants to clear the air about drug pricing with the consumer-focused extension of the Let's Talk About Cost campaign.
Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.
Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn't overwhelm trial organizers.
Merck's Keytruda combo therapy succeeds in Phase-III lung cancer trial; FDA launches pilot to address trial transparency; Spark's Luxturna overpriced, ICER says
BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche's breast cancer combo therapy
Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets
CVS/Aetna deal will affect healthcare benefits; lawmakers pressure DEA to curb painkiller supply; Allergan and Richter's Vraylar sees positive results for bipolar depression
FDA approves first topical skin growth treatment; Teva to cut 14,000 jobs; Novartis Oncology CEO resigns
FDA issues prescription drug promotion guidance; FDA approves first follow-on biologic of Lilly's Humalog; drugmakers allegedly hired nurses to promote drugs
FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance
UnitedHealth Group to buy DaVita primary care unit for $4.9 billion; Roche drug combo doubles lung-cancer survival in trial; study: FDA programs expedite drug approval
FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data
Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds
The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.
U.K. to be first to sell OTC Viagra; Regeneron offers startup scientific expertise; docs more likely to get poor marks when they reject patient requests
Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up
J&J to hold meeting on maintaining Remicade market share; Acorda ends development of Parkinson's drug; Darzalex notches positive first-line results
Docs biased against research from poor countries, study finds; Astellas probed over patient-assistance charity support; Acorda reports deaths in Parkinson's trial
Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head
Senator investigates Alkermes' opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide
The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.
Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug
FDA briefing document affirms diabetes drug's efficacy; J&J debuts new tools to improve adherence; AZ says cancer drug data was falsified
The answer: it depends on what phase the trial is in.
The CEO and founder of Antidote talks about what inspired him to start the company, which recently received funding from Merck.
One-third of clinical trials are never publicly registered; ICER revises PCSK9 cost-effectiveness analysis; flu shot linked to miscarriages
Alexion to cut 600 jobs; Sage Therapeutics' experimental seizure drug fails to meet expectations; Apple is interested in medical and health activity
Pfizer receives warning letter over EpiPen manufacturing; Opdivo kidney-cancer trial shows improved survival rates; cancer patients who discuss costs with physicians pay less
No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
Merck CEO leaves Trump's manufacturing council over Charlottesville response; researchers struggle to fill clinical trials for IO drugs; Roche shareholders sue over top-line results
FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Drugmakers inconsistently share clinical trial data; AstraZeneca's share price falls after Mystic results; some pregnancy apps share info with marketers
When you've figured out the difference, people will walk through fire for you, a mentor once told her.
The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial
Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate
Novartis reports positive Phase-III results for Eylea competitor; AZ faces "critical transition point" in MYSTIC trial; physician shortage expected to rise
Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
Consent forms and reimbursement are the main deterrents of offering the service.
Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative
Amgen's osteoporosis drug set back by safety issue; new FDA digital biz to hire 13 engineers; Celgene's MS drug bests Avonex in trial
FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs
GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products
QuintilesIMS partners with Salesforce; the E.U. to decide on new EMA location by June; drugmakers boost lobbying dollars in Q1
Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall
Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD
Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study
Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.
Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema
In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?
Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
Trial finds that Repatha reduces risk of heart attack and stroke; California measure would ban drug coupons in some cases; Takeda to limit price increases
Transportation barriers can limit patient involvement in clinical trials.
Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims
Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores
Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares
BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA
The drugmaker is using Propeller Health's sensor technology to find new ways to improve adherence in clinical studies.
The FDA approves new indication for Jardiance; Novartis' CAR-T therapy eliminates leukemia in 82% of patients in trial; doctors report risks associated with immunotherapy
How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy
Here's a look at 100 experimental therapies in late-stage clinical trials.
Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China
Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials
Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel
J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader
FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast
Jeanne Martel, president and partner at ClinicalMind, highlights her company's vision and role in communication and technology with MM&M's Jaimy Lee. This video was sponsored by ClinicalMind.
Amgen's Kyprolis fails to best Velcade in trial; diabetes drugs have lower than average FDA approval rate; Bayer's derm business draws interest
Anthem and Cigna accuse each other of violating merger terms; Alzheimer's experimental drug fails late-stage study; study calls for new approach to eradicate global epidemics
The organization said it used Facebook to identify participants for a study designed to identify biomarkers associated with Parkinson's disease.
Drugmakers routinely pay ghostwriters to write industry-funded research articles; Horizon to buy Raptor for $800 million; WellDoc partners with J&J
Only one new osteoporosis drug has been approved over the last six years.
OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children
Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana
Novo Nordisk attributes slow growth to biosimilars, pricing; Dentsu acquires majority stake in Merkle; AZ lung cancer drug fails late-stage trial
The event technology platform plans to integrate a conference note-taking app developed by AstraZeneca and DigitasLBi.
Researchers test Zika vaccine; Aetna contacts doctors who prescribe high rates of opioids; half of pediatric trials are never published or completed
The FDA declines to approve Novartis biosimilar; GSK partners with Apple's ResearchKit; drugmakers partner with Lyft for clinical trial participants
The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015
A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs
Drugmakers and tech companies are developing wearables and using popular fitness trackers like the Fitbit in clinical trials to gain insights about Parkinson's Disease.
Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug
Novartis CEO under pressure to restore investor confidence; Orexigen terminates obesity drug; startup invests in shaky cholesterol-drug class
Companies spend $2 billion per year recruiting patients for clinical trials. A survey of 702 adults, conducted from December 2015 to January 2016, points to a need for more awareness.
Monique Levy, who's spent more than a decade helping drugmakers understand technology shifts, has joined PatientsLikeMe, the online discussion platform for people with chronic illness.
The scientific services company expands its portfolio to include expertise in oncology clinical studies.